Topics
- Controlling the use of new antibiotics
- Antibody based strategies
- The latest treatment for Hepatitis C
- Horizons for antimicrobial resistance (AMR)
- Research and development in neglected diseases
- Public/private partnerships and how you can benefit from it
- Regulatory aspects of for new antimicrobials
- Nanoparticles approach to treat Gram-Positive and Gram-Negative pathogens
- Alternative models for tackling antimicrobial resistance
Who should Attend
Attendees responsible for medical microbiology, research, clinical development, antimicrobial therapeutics and business development, including:
- Senior Vice Presidents
- Chief Scientific Officers
- Research Scientists
- Chief Medical Officers
- R&D Project Managers
- Clinical Microbiologists
- Clinical Trials Managers
- Heads of Anti-Infectives Discovery
- Senior Vice Presidents of R&D
- Principal Scientists
- Product Managers
- Business Development Managers
